c-Met/HGFR

c-Met (hepatocyte growth factor receptor, HGFR) is a protein possesses tyrosine kinase activity. The primary single chain precursor protein is post-translationally cleaved to produce the alpha and beta subunits, which are disulfide linked to form the mature receptor. c-Met is a membrane receptor that is essential for embryonic development and wound healing. Hepatocyte growth factor (HGF) is the only known ligand of the c-Met receptor. c-Met is normally expressed by cells of epithelial origin, while expression of HGF is restricted to cells of mesenchymal origin. Upon HGF stimulation, c-Met induces several biological responses that collectively give rise to a program known as invasive growth.
c-Met/HGFR Inhibitors & Modulators

2-Phospho-L-ascorbic acid trisodium salt  (L-Ascorbic acid 2-phosphate trisodium salt; ...)  Cat. No.: HY-107837

Bioactivity: 2-Phospho-L-ascorbic acid trisodium salt acts as an antioxidant and a stimulator of hepatocyte growth factor (HGF) production.

Purity: 99.36%
Clinical Data: No Development Reported
Size: 10mM x 1mL in Water, 1 g

Altiratinib  (DCC-2701)  Cat. No.: HY-80791

Bioactivity: Altiratinib (DCC-2701) is a multi-targeted kinase inhibitor with IC\textsubscript{50} of 2.7, 8, 9.2, 9.3, 0.85, 4.6, 0.83 nM for MET, TIE2, VEGFR2, FLT3, Trk1, Trk2, and Trk3 respectively.

Purity: 95.95%
Clinical Data: Phase 1
Size: 10mM x 1mL in DMSO, 5 mg, 10 mg, 50 mg, 100 mg

AMG-208  Cat. No.: HY-12035

Bioactivity: AMG-208 is a potent small molecule c-Met inhibitor with an IC\textsubscript{50} of 9.3 nM. IC\textsubscript{50} value: 9.3 nM Target: c-Met in vitro: AMG-208 shows the potent inhibition of kinase c-Met activity with IC\textsubscript{50} of 9 nM in a cell-free assay. Besides, AMG-208 treatment also leads to the inhibition of HGF-mediated c-Met...

Purity: 99.34%
Clinical Data: Phase 2
Size: 10mM x 1mL in DMSO, 5 mg, 10 mg, 50 mg, 100 mg

AMG-337  Cat. No.: HY-18696

Bioactivity: AMG-337 is a potent and highly selective small molecule ATP-competitive MET kinase inhibitor. AMG 337 inhibits MET kinase activity with an IC\textsubscript{50} of < 5nM in enzymatic assays.

Purity: 99.26%
Clinical Data: Phase 2
Size: 10mM x 1mL in DMSO, 5 mg, 10 mg, 25 mg, 50 mg, 100 mg, 200 mg

BMS 777607  (BMS 817378)  Cat. No.: HY-12076

Bioactivity: BMS 777607 is a Met-related inhibitor for c-Met, Axl, Ron and Tyro3 with IC\textsubscript{50} of 3.9 nM, 1.1 nM, 1.8 nM and 4.3 nM, respectively, and 40-fold more selective for Met-related targets than Lck, VEGFR-2, and TrkA/B, with more than 500-fold greater selectivity versus all other receptor and non receptor...

Purity: 99.48%
Clinical Data: Phase 2
Size: 10mM x 1mL in DMSO, 5 mg, 10 mg, 50 mg, 100 mg

BMS-794833  Cat. No.: HY-10497

Bioactivity: BMS-794833 is a VEGFR2 and Met inhibitor extracted from patent WO2009094417, compound example 1; has IC\textsubscript{50} of 15 and 1.7 nM, respectively.

Purity: 99.82%
Clinical Data: No Development Reported
Size: 10mM x 1mL in DMSO, 5 mg, 10 mg, 50 mg, 100 mg

c-Kit-IN-1  Cat. No.: HY-15240

Bioactivity: c-Kit-IN-1 is a potent inhibitor of c-Kit and c-Met with IC\textsubscript{50} of <200 nM.

Purity: 98.46%
Clinical Data: Phase 1
Size: 10mM x 1mL in DMSO, 5 mg, 10 mg, 50 mg, 100 mg

c-Met inhibitor 1  Cat. No.: HY-15735

Bioactivity: c-Met inhibitor 1 is an inhibitor of the c-Met receptor signaling pathway useful for the treatment of cancer including gastric, glioblastoma, and pancreatic cancer.

Purity: 98.72%
Clinical Data: No Development Reported
Size: 10mM x 1mL in DMSO, 5 mg, 10 mg, 50 mg, 100 mg

c-Met-IN-2  Cat. No.: HY-101773

Bioactivity: c-Met-IN-2 is a potent, selective and orally available c-Met inhibitor, with an IC\textsubscript{50} of 0.6 nM, with antitumor activity.

Purity: >98%
Clinical Data: No Development Reported
Size: 250 mg, 500 mg

Cabozantinib  (XL184; BMS-907351)  Cat. No.: HY-13016

Bioactivity: Cabozantinib is a potent multiple receptor tyrosine kinases inhibitor that inhibits VEGFR2, c-Met, Kit, Axl and Flt3 with IC\textsubscript{50} of 0.035, 1.3, 4.6, 7 and 11.3 nM, respectively.

Purity: 99.92%
Clinical Data: Launched
Size: 10mM x 1mL in DMSO, 5 mg, 10 mg, 50 mg, 100 mg, 200 mg
**Capmatinib**  
*(INCB28060; INC-280)*  
Cat. No.: HY-13404  

**Bioactivity:** Capmatinib (INCB28060) is a potent and selective c-MET kinase inhibitor. Capmatinib (INCB28060) inhibits c-MET kinase activity with an average $IC_{50}$ of 0.13 nM.  

**Purity:** 99.84%  
**Clinical Data:**  
- Phase 4  
- Size: 10mM x 1mL in DMSO, 5 mg, 10 mg, 50 mg, 100 mg, 200 mg

<table>
<thead>
<tr>
<th>Size</th>
<th>Purity: 98.25%</th>
<th>Clinical Data: No Development Reported</th>
<th>Clinical Data: No Development Reported</th>
</tr>
</thead>
<tbody>
<tr>
<td>10mM x 1mL in DMSO</td>
<td>5 mg</td>
<td>10 mg, 50 mg</td>
<td>100 mg</td>
</tr>
</tbody>
</table>

**CEP-40783**  
*(RXDX-106)*  
Cat. No.: HY-100946  

**Bioactivity:** CEP-40783 is a potent, selective and orally available inhibitor of AXL and c-Met with $IC_{50}$ values of 7 nM and 12 nM, respectively.  

**Purity:** 98.25%  
**Clinical Data:**  
- No Development Reported  
- Size: 10mM x 1mL in DMSO, 5 mg, 10 mg, 50 mg, 100 mg

**Crizotinib**  
*(PF-02341066)*  
Cat. No.: HY-50878  

**Bioactivity:** Crizotinib is a potent inhibitor of c-Met and ALK with an $IC_{50}$ of 11 nM and 24 nM in cell-based assays, respectively.  

**Purity:** 99.97%  
**Clinical Data:** Launched  
**Size:**  
- 10mM x 1mL in DMSO,  
- 10 mg, 50 mg, 100 mg, 200 mg, 500 mg

**Crizotinib hydrochloride**  
*(PF-02341066 hydrochloride)*  
Cat. No.: HY-50878A  

**Bioactivity:** Crizotinib hydrochloride is a potent inhibitor of c-Met and ALK with $IC_{50}$ of 11 nM and 24 nM in cell-based assays, respectively.  

**Purity:** 99.86%  
**Clinical Data:** Launched  
**Size:**  
- 10mM x 1mL in DMSO,  
- 10 mg, 50 mg, 100 mg, 200 mg, 500 mg

**CSF1R-IN-2**  
Cat. No.: HY-111787  

**Bioactivity:** CSF1R-IN-2 (compound 5) is an oral-active inhibitor of SRC, MET and c-FMS, with $IC_{50}$ values of 0.12 nM, 0.14 nM and 0.76 nM for SRC, MET and c-FMS respectively.  

**Purity:** >98%  
**Clinical Data:** No Development Reported  
**Size:**  
- 250 mg, 500 mg

**Dihexa**  
*(PNB-0408; N-hexanoic-Try-Ile-(6)-amino hexanoic amide; Hexanoyl-Tyr-Ile-Ahx-NH2)*  
Cat. No.: HY-16969  

**Bioactivity:** Dihexa is an orally active, blood-brain barrier-permeable angiotensin IV analog; exhibits high affinity binding hepatocyte growth factor (HGF) with a $K_D$ of 65 pM.  

**Purity:** 98.0%  
**Clinical Data:** No Development Reported  
**Size:**  
- 10mM x 1mL in DMSO,  
- 2 mg, 5 mg, 10 mg, 50 mg, 100 mg

**Ensartinib**  
*(X-396)*  
Cat. No.: HY-103714  

**Bioactivity:** Ensartinib (X-396) is a potent and dual ALK/ MET inhibitor with $IC_{50}$ of <0.4 nM and 0.74 nM, respectively.  

**Purity:** >98%  
**Clinical Data:** No Development Reported  
**Size:**  
- 250 mg, 500 mg

**Ensartinib hydrochloride**  
*(X-396 hydrochloride)*  
Cat. No.: HY-103714A  

**Bioactivity:** Ensartinib hydrochloride (X-396 hydrochloride) is a potent and dual ALK/ MET inhibitor with $IC_{50}$ of <0.4 nM and 0.74 nM, respectively.  

**Purity:** 98.51%  
**Clinical Data:** No Development Reported  
**Size:**  
- 2 mg, 5 mg, 10 mg

**Foretinib**  
*(XL880; GSK1363089; GSK089; EXEL-2880)*  
Cat. No.: HY-10338  

**Bioactivity:** Foretinib is a multi-target tyrosine kinase inhibitor with $IC_{50}$ of 0.4 nM and 0.9 nM for Met and KDR.  

**Purity:** 99.81%  
**Clinical Data:** Phase 2  
**Size:**  
- 10mM x 1mL in DMSO,  
- 5 mg, 10 mg, 50 mg, 100 mg

**Glesatinib hydrochloride**  
*(MGCD265 hydrochloride)*  
Cat. No.: HY-19642A  

**Bioactivity:** Glesatinib hydrochloride is an inhibitor of the MET and Axl receptor tyrosine kinase pathways, which drive tumour growth when altered. Target: MET, Axl Glesatinib is an orally bioavailable, small-molecule, multitargeted tyrosine kinase inhibitor with potential antineoplastic activity. MGCD265...

**Purity:** 98.25%  
**Clinical Data:** No Development Reported  
**Size:**  
- 10mM x 1mL in DMSO,  
- 1 mg, 5 mg, 10 mg, 50 mg, 100 mg
| **Glumetinib**  
(SCC244) | **Cat. No.:** HY-116000 |
<table>
<thead>
<tr>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Bioactivity:</strong> Glumetinib (SCC244) is a potent and highly selective c-Met kinase inhibitor with an IC₅₀ of 0.42 nM. Glumetinib shows antitumor activity and a superior safety margin [1].</td>
<td></td>
</tr>
</tbody>
</table>
| **Purity:** >98%  
| **Clinical Data:** No Development Reported  
| **Size:** 500 mg, 100 mg, 250 mg |

| **Golvatinib**  
(E-7050) | **Cat. No.:** HY-13068 |
<table>
<thead>
<tr>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Bioactivity:</strong> Golvatinib (E-7050) is a potent dual inhibitor of both c-Met and VEGFR2 kinases with IC₅₀ of 14 and 16 nM, respectively.</td>
<td></td>
</tr>
</tbody>
</table>
| **Purity:** 99.29%  
| **Clinical Data:** Phase 2  
| **Size:** 10mM x 1mL in DMSO, 5 mg, 10 mg, 50 mg, 100 mg |

| **JNJ-38877605**  
Cat. No.: HY-50683 |
|---|---|
| **Bioactivity:** JNJ-38877605 is an ATP-competitive inhibitor of c-Met with IC₅₀ of 4 nM, 600-fold selective for c-Met than 200 other tyrosine and serine-threonine kinases. IC₅₀ value: 4 nM [1]  
Target: c-Met in vitro: JNJ-38877605 shows more than 600-fold selectivity for c-Met compared with more than 200 other... |
| **Purity:** 99.99%  
| **Clinical Data:** Phase 1  
| **Size:** 10mM x 1mL in DMSO, 5 mg, 10 mg, 50 mg, 100 mg |

| **Merestinib**  
(LY2801653) | **Cat. No.:** HY-15514 |
<table>
<thead>
<tr>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Bioactivity:</strong> Merestinib (LY2801653) is a type-II ATP competitive, slow-off inhibitor of MET tyrosine kinase with a dissociation constant (Kᵦ) of 2 nM.</td>
<td></td>
</tr>
</tbody>
</table>
| **Purity:** 99.99%  
| **Clinical Data:** Phase 2  
| **Size:** 10mM x 1mL in DMSO, 5 mg, 10 mg, 50 mg, 100 mg |

| **MGCD-265 analog**  
Cat. No.: HY-10991 |
<table>
<thead>
<tr>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Bioactivity:</strong> MGCD-265-analog (structurally related to MGCD-265) is an orally bioavailable multitargeted tyrosine kinase inhibitor with potential antineoplastic activity with IC₅₀ of 29 nM and 10 nM for c-Met and VEGFR2, respectively. IC₅₀ value:10 nM (VEGFR2), 29 nM(c-Met) [1] Target:VEGFR, c-Met in vivo:...</td>
<td></td>
</tr>
</tbody>
</table>
| **Purity:** 96.53%  
| **Clinical Data:** No Development Reported  
| **Size:** 10mM x 1mL in DMSO, 2 mg, 5 mg, 10 mg, 50 mg |

| **MK-2461**  
Cat. No.: HY-50703 |
<table>
<thead>
<tr>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Bioactivity:</strong> MK-2461 is a novel ATP-competitive multitargeted inhibitor of activated c-Met with a mean IC₅₀ of 2.5 nM.</td>
<td></td>
</tr>
</tbody>
</table>
| **Purity:** 99.92%  
| **Clinical Data:** Phase 2  
| **Size:** 10mM x 1mL in DMSO, 2 mg, 5 mg, 10 mg, 25 mg, 50 mg |

| **MK-8033**  
Cat. No.: HY-13299 |
<table>
<thead>
<tr>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Bioactivity:</strong> MK-8033 is a novel and specific dual ATP competitive c-Met/Ron inhibitor (IC₅₀=1 nM WT c-Met) under investigation as a treatment for cancer. IC₅₀ Value: 1 nM (WT c-Met), 2.0 nM (c-Met N1100Y) [1] Target: c-Met/Ron in vitro: MK-8033 binds 3-fold more tightly to phosphorylated c-Met kinase domain (Kᵦ=...</td>
<td></td>
</tr>
</tbody>
</table>
| **Purity:** 98.0%  
| **Clinical Data:** Phase 1  
| **Size:** 10mM x 1mL in DMSO, 5 mg, 10 mg, 50 mg |

| **Merestinib dihydrochloride**  
(LY2801653 (dihydrochloride)) | **Cat. No.:** HY-15514A |
<table>
<thead>
<tr>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Bioactivity:</strong> Merestinib dihydrochloride (LY2801653 dihydrochloride) is a type-II ATP competitive, slow-off inhibitor of MET tyrosine kinase with a dissociation constant (Kᵦ) of 2 nM.</td>
<td></td>
</tr>
</tbody>
</table>
| **Purity:** 99.02%  
| **Clinical Data:** Phase 2  
| **Size:** 10mM x 1mL in DMSO, 5 mg, 10 mg, 50 mg, 100 mg |

| **MK-8033 hydrochloride**  
Cat. No.: HY-13299A |
<table>
<thead>
<tr>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Bioactivity:</strong> MK-8033 Hcl is a novel and specific dual ATP competitive c-Met/Ron inhibitor (IC₅₀=1 nM WT c-Met) under investigation as a treatment for cancer.</td>
<td></td>
</tr>
</tbody>
</table>
| **Purity:** >98%  
| **Clinical Data:** Phase 1  
| **Size:** 5 mg, 10 mg, 50 mg |
Ningetinib
Cat. No.: HY-107145A

Bioactivity: Ningetinib is a potent, orally bioavailable small molecule tyrosine kinase inhibitor (TKI) with IC50s of 6.7, 1.9 and <1.0 nM for c-Met, VEGFR2 and Axl, respectively.

Purity: 98.75%
Clinical Data: No Development Reported
Size: 10mM x 1mL in DMSO, 5 mg, 10 mg, 25 mg, 50 mg, 100 mg

Ningetinib Tosylate
Cat. No.: HY-107145

Bioactivity: Ningetinib Tosylate is a potent, orally bioavailable small molecule tyrosine kinase inhibitor (TKI) with IC50s of 6.7, 1.9 and <1.0 nM for c-Met, VEGFR2 and Axl, respectively.

Purity: 99.88%
Clinical Data: No Development Reported
Size: 10mM x 1mL in DMSO, 5 mg, 10 mg, 25 mg, 50 mg, 100 mg

NPS-1034
Cat. No.: HY-100509

Bioactivity: NPS-1034 is a dual inhibitor of AXL and MET with IC50s of 10.3 and 48 nM, respectively.

Purity: 98.0%
Clinical Data: No Development Reported
Size: 10mM x 1mL in DMSO, 5 mg, 10 mg, 25 mg, 50 mg, 100 mg

NVP-BVU972
Cat. No.: HY-15456

Bioactivity: NVP-BVU972 is a selective and potent Met inhibitor (IC50 = 14 nM). Antitumor agents.

Purity: 97.35%
Clinical Data: No Development Reported
Size: 10mM x 1mL in DMSO, 5 mg, 10 mg, 50 mg

PF-04217903
Cat. No.: HY-12017

Bioactivity: PF-04217903 is a selective ATP-competitive c-Met inhibitor with IC50 of 4.8 nM, susceptible to oncogenic mutations (no activity to Y1230C mutant). IC50 value: 4.8 nM [1] Target: in vitro: Being more selective than staurosporine or PF-02341066, PF-04217903 displays >1000-fold selectivity for c-Met over...

Purity: 99.59%
Clinical Data: Phase 1
Size: 10mM x 1mL in DMSO, 5 mg, 10 mg, 50 mg, 100 mg

PF-04217903 methanesulfonate
Cat. No.: HY-12017A

Bioactivity: PF-04217903 methanesulfonate is a selective ATP-competitive c-Met inhibitor with IC50 of 4.8 nM, susceptible to oncogenic mutations (no activity to Y1230C mutant).

Purity: 99.87%
Clinical Data: Phase 1
Size: 10mM x 1mL in DMSO, 5 mg, 10 mg, 50 mg, 100 mg

PHA-665752
Cat. No.: HY-11107

Bioactivity: PHA-665752 is a potent, selective and ATP-competitive c-Met inhibitor with an IC50 of 9 nM.

Purity: 96.50%
Clinical Data: No Development Reported
Size: 10mM x 1mL in DMSO, 10 mg, 50 mg, 100 mg

S49076
Cat. No.: HY-12965

Bioactivity: S49076 is a novel, potent inhibitor of MET, AXL/MER, and FGFR1/2/3 with IC50 values below 20 nM.

Purity: 98.99%
Clinical Data: No Development Reported
Size: 10mM x 1mL in DMSO, 2 mg, 5 mg, 10 mg, 50 mg, 100 mg

SAR125844
Cat. No.: HY-16446

Bioactivity: SAR125844 is a potent, highly selective, reversible and ATP-competitive MET receptor tyrosine kinase (RTK) inhibitor, with an IC50 of 4.2 nM. Shows inhibition of MET autophosphorylation in cell-based assays [1].

Purity: 99.03%
Clinical Data: No Development Reported
Size: 10mM x 1mL in DMSO, 5 mg, 10 mg, 50 mg, 100 mg

Savolitinib
(Volitinib; HMPL-504; AZD-6094)
Cat. No.: HY-15959

Bioactivity: Savolitinib (AZD6094) is a highly potent and selective c-Met inhibitor with an IC50 of 5 nM.

Purity: 98.45%
Clinical Data: Phase 3
Size: 10mM x 1mL in DMSO, 5 mg, 10 mg, 50 mg, 100 mg
| **SCR-1481B1**  
(c-Met inhibitor 2) | **Cat. No.: HY-18711A** |
|------------------|-------------------------|
| **Bioactivity:**  
SCR-1481B1 (c-Met inhibitor 2) is a potent compound that has activity against cancers dependent upon Met activation and also has activity against cancers as a VEGFR inhibitor. |
| **Purity:** 99.99% |
| **Clinical Data:**  
No Development Reported |
| **Size:** 10mM x 1mL in DMSO, 5 mg, 10 mg, 50 mg, 100 mg |

| **SGX-523**  
Cat. No.: HY-12019 |
|------------------|
| **Bioactivity:**  
SGX-523 is a selective Met inhibitor with IC$_{50}$ of 4 nM, no activity to BRAFV599E, c-Raf, Abl and p38α. IC$_{50}$ value: 4 nM [1] Target: Met in vitro: SGX-523 belongs to the class of c-Met/hepatocyte growth factor receptor (HGFR) tyrosine kinase inhibitors. SGX-523 stabilizes MET in a unique inactive... |
| **Purity:** 98.0% |
| **Clinical Data:**  
Phase 3 |
| **Size:** 10mM x 1mL in DMSO, 2 mg, 5 mg, 10 mg, 50 mg, 100 mg |

| **SU11274**  
(PKI-SU11274) | **Cat. No.: HY-12014** |
|------------------|-------------------------|
| **Bioactivity:**  
SU11274 is a selective Met inhibitor with IC$_{50}$ of 10 nM, but has no effects on PDGFRβ, EGFR or Tie2. |
| **Purity:** 98.09% |
| **Clinical Data:**  
No Development Reported |
| **Size:** 10mM x 1mL in DMSO, 10 mg, 50 mg, 100 mg |

| **TAS-115 mesylate**  
(TAS-115 methanesulfonate) | **Cat. No.: HY-12423A** |
|------------------|-------------------------|
| **Bioactivity:**  
TAS-115 mesylate is a potent VEGFR and hepatocyte growth factor receptor (c-Met/HGFR)-targeted kinase inhibitor with IC$_{50}$ of 30 and 32 nM for rVEGFR2 and rMET, respectively. |
| **Purity:** 99.15% |
| **Clinical Data:**  
No Development Reported |
| **Size:** 10mM x 1mL in DMSO, 5 mg, 10 mg, 25 mg, 50 mg, 100 mg |

| **Tivantinib**  
(ARQ 197) | **Cat. No.: HY-50686** |
|------------------|-------------------------|
| **Bioactivity:**  
Tivantinib is a novel and highly selective c-Met tyrosine kinase inhibitor with $K_I$ of 335 nM. |
| **Purity:** 99.39% |
| **Clinical Data:**  
Phase 3 |
| **Size:** 10mM x 1mL in DMSO, 5 mg, 10 mg, 50 mg, 100 mg, 200 mg, 500 mg |

| **Tepotinib**  
(EMD-1214063) | **Cat. No.: HY-14721** |
|------------------|
| **Bioactivity:**  
Tepotinib (EMD-1214063) is a potent and selective c-Met inhibitor with IC$_{50}$ of 4 nM, >200-fold selective for c-Met than IRAK4, TrkA, Axl, IRAK1, and Mer. |
| **Purity:** 99.80% |
| **Clinical Data:**  
Phase 2 |
| **Size:** 10mM x 1mL in DMSO, 5 mg, 10 mg, 50 mg, 100 mg |

| **Tyrosine kinase inhibitor** | **Cat. No.: HY-10421** |
|------------------|
| **Bioactivity:**  
A Tyrosine kinase inhibitor. |
| **Purity:** 99.78% |
| **Clinical Data:**  
No Development Reported |
| **Size:** 10mM x 1mL in DMSO, 5 mg |

**Bioactivity:** SCR-1481B1 is a potent c-Met inhibitor that has activity against cancers dependent upon Met activation and also has activity against cancers as a VEGFR inhibitor.

**Bioactivity:** SGX-523 is a selective Met inhibitor with IC$_{50}$ of 4 nM, no activity to BRAF V599E, c-Raf, Abl and p38α. IC$_{50}$ value: 4 nM [1] Target: Met in vitro: SGX-523 belongs to the class of c-Met/hepatocyte growth factor receptor (HGFR) tyrosine kinase inhibitors. SGX-523 stabilizes MET in a unique inactive form.

**Bioactivity:** SU11274 is a selective Met inhibitor with IC$_{50}$ of 10 nM, but has no effects on PDGFRβ, EGFR or Tie2.

**Bioactivity:** TAS-115 mesylate is a potent VEGFR and hepatocyte growth factor receptor (c-Met/HGFR)-targeted kinase inhibitor with IC$_{50}$ of 30 and 32 nM for rVEGFR2 and rMET, respectively.

**Bioactivity:** Tivantinib is a novel and highly selective c-Met tyrosine kinase inhibitor with IC$_{50}$ of 335 nM.

**Bioactivity:** Tepotinib (EMD-1214063) is a potent and selective c-Met inhibitor with IC$_{50}$ of 4 nM, >200-fold selective for c-Met than IRAK4, TrkA, Axl, IRAK1, and Mer.

**Bioactivity:** X-376 is a potent and dual ALK/ MET inhibitor with IC$_{50}$ of 0.61 nM and 0.69 nM, respectively.